Kathy Miller
8 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers (NCT05846789) | Kathy Miller | 2024-07-02 |
| Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer (NCT04134884) | Kathy Miller | 2020-04-01 |
Track Kathy Miller automatically
Every clearance here is in the API, with alerts when new ones post.